长城会 2015:LDL-C ,越低越好吗?

2015-11-03 CMT 中国医学论坛报

血脂水平异常是心血管病发生中的重要危险因素,也是历年长城会的热点议题。在昨天“对调脂治疗的再认识”专场,多位专家围绕调脂治疗进行了阐述。北京大学人民医院陈红教授为大家带来的题为“LDL-C,越低越好吗?”的报告备受参会者关注。 陈红教授介绍,100多年前俄国病理学家Antischkow首先提出胆固醇参与动脉粥样硬化(AS)的发生发展,其后动物实验、流行病学研究、人体干预试验均证实胆固醇是

血脂水平异常是心血管病发生中的重要危险因素,也是历年长城会的热点议题。在昨天“对调脂治疗的再认识”专场,多位专家围绕调脂治疗进行了阐述。北京大学人民医院陈红教授为大家带来的题为“LDL-C,越低越好吗?”的报告备受参会者关注。

陈红教授介绍,100多年前俄国病理学家Antischkow首先提出胆固醇参与动脉粥样硬化(AS)的发生发展,其后动物实验、流行病学研究、人体干预试验均证实胆固醇是AS的危险因素,降低循环中胆固醇水平成为近代AS防治的重要策略。基于包含17万患者的26项随机对照试验(RCT)的荟萃分析显示,低密度脂蛋白胆固醇(LDL-C)每降低1 mmol/L,5年内冠心病主要事件降低22%。IMPROVE-IT研究显示,LDL-C降至53.2 mg/dL仍可较LDL-C为69.9 mg/dL的人群进一步获益。近年来相关指南中LDL-C的靶目标也由130 mg/dL降至70 mg/dL。随着包括PCSK9抑制剂在内的新型强效降LDL-C的药物应运而生,人们有能力把LDL-C降得更低,但对于整体健康而言,LDL-C的合适水平仍是一个无解的问题。

尽管LDL-C的最低安全阈值并无明确答案,但理论上不应该“越低越好”。首先,胆固醇是人体不可或缺的物质,除神经元细胞外人体每一个细胞都合成胆固醇。其次,大脑的形态和功能需要胆固醇。人体胆固醇总量的23%在大脑内,主要存在于神经髓鞘,另外也存在于神经元和星形胶质细胞中,发挥维护脑细胞复杂形态和突触传导的功能。虽然循环中的LDL-C无法进入脑组织,但降低循环LDL-C的药物可以。所以,在降低循环LDL-C水平的同时不可避免要干扰脑组织胆固醇代谢。

最后,陈教授指出,“LDL-C越低越好”这一假设目前还缺乏支持依据,但在一定范围内“LDL-C低一些好”是公认的。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=62966, encodeId=8bb1629669d, content=很好?, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c5d1685693, createdName=1de46324m33(暂无匿称), createdTime=Wed Feb 03 05:50:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322742, encodeId=ed131322e42b9, content=<a href='/topic/show?id=355b96891fe' target=_blank style='color:#2F92EE;'>#长城会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96891, encryptionId=355b96891fe, topicName=长城会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu Nov 05 02:21:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422530, encodeId=54df14225300e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Nov 05 02:21:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42425, encodeId=94584242589, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ded1659654, createdName=周可儿, createdTime=Tue Nov 03 16:41:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
    2016-02-03 1de46324m33(暂无匿称)

    很好?

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=62966, encodeId=8bb1629669d, content=很好?, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c5d1685693, createdName=1de46324m33(暂无匿称), createdTime=Wed Feb 03 05:50:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322742, encodeId=ed131322e42b9, content=<a href='/topic/show?id=355b96891fe' target=_blank style='color:#2F92EE;'>#长城会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96891, encryptionId=355b96891fe, topicName=长城会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu Nov 05 02:21:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422530, encodeId=54df14225300e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Nov 05 02:21:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42425, encodeId=94584242589, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ded1659654, createdName=周可儿, createdTime=Tue Nov 03 16:41:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=62966, encodeId=8bb1629669d, content=很好?, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c5d1685693, createdName=1de46324m33(暂无匿称), createdTime=Wed Feb 03 05:50:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322742, encodeId=ed131322e42b9, content=<a href='/topic/show?id=355b96891fe' target=_blank style='color:#2F92EE;'>#长城会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96891, encryptionId=355b96891fe, topicName=长城会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu Nov 05 02:21:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422530, encodeId=54df14225300e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Nov 05 02:21:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42425, encodeId=94584242589, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ded1659654, createdName=周可儿, createdTime=Tue Nov 03 16:41:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
    2015-11-05 zhwj
  4. [GetPortalCommentsPageByObjectIdResponse(id=62966, encodeId=8bb1629669d, content=很好?, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c5d1685693, createdName=1de46324m33(暂无匿称), createdTime=Wed Feb 03 05:50:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322742, encodeId=ed131322e42b9, content=<a href='/topic/show?id=355b96891fe' target=_blank style='color:#2F92EE;'>#长城会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96891, encryptionId=355b96891fe, topicName=长城会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef33504, createdName=wsusan1966, createdTime=Thu Nov 05 02:21:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422530, encodeId=54df14225300e, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Thu Nov 05 02:21:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42425, encodeId=94584242589, content=学到了, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ded1659654, createdName=周可儿, createdTime=Tue Nov 03 16:41:00 CST 2015, time=2015-11-03, status=1, ipAttribution=)]
    2015-11-03 周可儿

    学到了

    0

相关资讯

Circulation:依折麦布/辛伐他汀可以更好地降低LDL-C和hs-CRP(IMPROVE-IT试验)

他汀类药物可以降低低密度脂蛋白胆固醇(LDL-C)和高敏C反应蛋白(hs-CRP);将依折麦布加入到他汀类药物中能够进一步降低LDL-C和hs-CRP。研究人员进行了一项达到LDL-C及hs-CRP的目标和改善结果的预先设定的辛伐他汀和依折麦布/辛伐他汀之间的关系的分析:Vytorin作用国际试验(IMPROVE-IT)。该IMPROVE-IT试验随机分配18144例急性冠脉综合征患者接受辛伐他汀

NEJM:PCSK9抑制剂Evolocumab可显著降低LDL-C水平和心血管事件(OSLER研究)

Evolocumab是一种单克隆抗体,为PCSK9抑制剂,先前短期研究发现,Evolocumab可明显降低低密度脂蛋白胆固醇(LDL-C)水平。为了探究Evolocumab的长期有效性和安全性,研究者进行了两项非盲、随机的延伸试验,以获取数据分析该问题。

NEJM:PCSK9抑制剂Alirocumab联合大剂量他汀可显著降低LDL-C水平

Alirocumab是一种单克隆抗体,为前蛋白转化酶枯草溶菌素 9(PCSK9)抑制剂,先前有研究发现,Alirocumab可降低使用他汀类药物治疗的患者的低密度脂蛋白胆固醇(LDL-C)水平。Robinson JG等人进行了一项随机对照试验以探究Alirocumab的有效性和安全性。

Circulation:TC/HDL-C有望为LDL-C和非HDL-C提供潜在额外信息

从标准脂质谱中可常规获取总胆固醇/高密度脂蛋白胆固醇(TC/HDL-C)比、估计低密度脂蛋白胆固醇(LDL-C)和非HDL-C。美国一项研究表明,在接受先进脂质检测的美国成人当前横断面大数据分析中,患者水平不一致性程度提示TC/HDL-C有望为LDL-C和非HDL-C提供潜在的额外信息;未来需行进一步的研究以确定此观察结果的临床意义。相关论文7月2日在线发表于《循环》(Circulation)。

FDA:Repatha——心血管疾病患者的福音来了

Repatha,其通用名称为Evolocumab,是无法控制低密度脂蛋白胆固醇(LDL-C)的高胆固醇血症患者目前的治疗用药。FDA建议,健康合理的饮食联合使用他汀类药物治疗杂合子家族性高胆固醇血症(heFH)患者,纯合子家族性高胆固醇血症(HoFH)患者或患动脉粥样硬化性心血管疾病(如心脏病发作或中风)的患者需要额外药物来降低LDL-C水平。HeFH和HoFH患者体内LDL-C高浓度是由于遗传因

孙艺红/胡大一:降低LDL-C是硬道理

一、国际指南的变化与异同过去一年中,国际多个学术组织陆续更新了血脂异常临床治疗指南。这些指南因制定策略和方法不同,临床管理策略建议也各有特色。其共同之处包括:(1)调脂治疗主要目的是降低ASCVD风险。ASCVD不仅包括冠心病,也包括动脉粥样硬化所致缺血性卒中和外周动脉粥样硬化性疾病。且糖尿病和慢性肾病患者也被列为与ASCVD危险等同的极高危人群。(2)推荐他汀类药物作为降低ASCVD风险的主